Copyright
©The Author(s) 2019.
World J Gastrointest Surg. Jun 27, 2019; 11(6): 287-295
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.287
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.287
Biomarker criteria | |
TTV/AFP[18] | Total tumor volume ≤ 115 cm3 and AFP ≤ 400 ng/mL |
AFP-TTD[37] | Total tumor diameter ≤ 8 cm and AFP ≤ 400 ng/mL |
Warsaw[38] | Outside the Milan criteria but within the UCSF/ Up-to-7 criteria with AFP < 100 ng/mL |
NCCK[39] | Negative PET/CT findings and the total tumor size < 10 cm |
Kyoto[19] | ≤ 10 tumors, all of which ≤ 5 cm in diameter, and serum DCP ≤ 400 mAU/mL |
Kyushu university[40] | Tumor diameter ≤ 5 cm and serum DCP ≤ 300 mAU/mL |
Extended Toronto[41] | No size-number limitation, no vascular invasion, no extrahepatic disease, no cancer-related symptoms, biopsy of the largest tumor not poorly differentiated |
- Citation: Mullath A, Krishna M. Hepatocellular carcinoma – time to take the ticket. World J Gastrointest Surg 2019; 11(6): 287-295
- URL: https://www.wjgnet.com/1948-9366/full/v11/i6/287.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v11.i6.287